Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
François Rabelais University, Tours, France.
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00710-19. Print 2019 Aug.
is a challenge for clinicians due to increasing drug resistance and dwindling treatment options. We report on the activity of MEDI3902, an antibody targeting type 3 secretion protein PcrV and Psl exopolysaccharide, in rabbit bloodstream and lung infection models. MEDI3902 prophylaxis or treatment was protective in both acute models and exhibited enhanced activity when combined with a subtherapeutic dose of meropenem. These findings further support MEDI3902 for the prevention or treatment of serious infections.
是临床医生面临的挑战，因为耐药性不断增加和治疗选择日益减少。我们报告了靶向 3 型分泌蛋白 PcrV 和 Psl 多糖的抗体 MEDI3902 在兔血流传感和肺感染模型中的活性。MEDI3902 的预防或治疗在两种急性模型中均具有保护作用，并且当与亚治疗剂量的美罗培南联合使用时，其活性增强。这些发现进一步支持 MEDI3902 用于预防或治疗严重 感染。
